Vaginal dryness in menopause is caused by the decline in estrogen that maintains vaginal tissue thickness, lubrication, and elasticity. When estrogen drops, the vaginal walls thin, natural moisture decreases, and the vaginal pH shifts to a more alkaline state that disrupts the protective microbiome. This is part of a broader condition called Genitourinary Syndrome of Menopause (GSM). Unlike hot flashes, vaginal dryness is progressive — it worsens without treatment. Effective options range from over-the-counter vaginal moisturizers to low-dose vaginal estrogen, which the FDA cleared of its boxed warning in November 2025.
You may have noticed it gradually. Sex felt different — less comfortable, then actively painful. Or the dryness showed up outside of sex entirely: an irritation that wouldn’t go away, a burning when you wiped, an itch that had no visible cause, a sensitivity to clothing that never bothered you before.
Or maybe it arrived more suddenly — after a surgical procedure, after chemotherapy, after your periods stopped — and you assumed it was temporary. You waited for it to pass. It didn’t.
Vaginal dryness is the most commonly reported symptom of Genitourinary Syndrome of Menopause (GSM). Studies estimate that it affects 85 to 93% of women who experience genitourinary changes during and after menopause. And yet only about 25% of women with these symptoms ever receive adequate treatment — because they are embarrassed to raise it, because they assume it’s just aging, or because their doctor never asks.
This article is going to change that for you. I’m going to explain exactly what is happening in your tissue, why it gets worse over time, and what the evidence says about every major treatment option — from what you can buy today without a prescription to the gold-standard therapies your doctor should be offering.
What Estrogen Actually Does for Your Vaginal Tissue
To understand vaginal dryness in menopause, you need to understand what estrogen was doing for your vaginal tissue before it declined — because estrogen was doing a lot more than you were probably told.
The vaginal walls are lined with layers of epithelial cells. Estrogen stimulates those cells to proliferate, keeping the vaginal lining thick and resilient. Estrogen also promotes blood flow to the vaginal walls, which supports the transudation process — the mechanism by which moisture seeps through the vaginal lining to keep the surface lubricated. On top of this, estrogen maintains the vaginal pH in a healthy acidic range (approximately 3.5 to 4.5), which supports the dominance of Lactobacillus bacteria — the protective microbiome that keeps infections at bay.
When estrogen declines, every one of these functions is affected. The cell layers thin. Blood flow decreases. Moisture production drops. The pH shifts alkaline. The Lactobacillus population declines. The tissue becomes drier, more fragile, more easily irritated, and more susceptible to both injury and infection.
This is not wear and tear. It is not a consequence of disuse. It is a tissue-level change driven by the loss of a specific hormone — and it has a name.
This Is Part of a Bigger Picture: GSM
Vaginal dryness is the most visible symptom of a broader condition called Genitourinary Syndrome of Menopause (GSM). GSM describes the full range of vaginal, vulvar, and urinary changes caused by estrogen decline. It was formally named in 2014 by The Menopause Society and the International Society for the Study of Women’s Sexual Health, replacing the older and less complete terms “vaginal atrophy” and “atrophic vaginitis” (Portman & Gass, Menopause, 2014).
Understanding that vaginal dryness is part of GSM matters for two reasons. First, it means that dryness is often accompanied by other symptoms — painful sex, vulvar irritation, urinary urgency, recurrent UTIs — that have the same root cause. Treating the dryness in isolation without addressing the underlying estrogen deficit may leave other symptoms unresolved. Second, it gives you a clinical term to use with your doctor — and that changes the conversation.
A detailed explainer on GSM itself is available in our dedicated article.
Why This Gets Worse — Not Better
This is the piece of information that most women never receive, and it is the most important reason to act rather than wait.
Hot flashes are driven by the vasomotor system adjusting to fluctuating estrogen. For many women, they peak and then gradually subside over several years. There is a natural adaptation.
Vaginal dryness has no such adaptation. The estrogen those tissues need is not coming back after menopause. Without treatment, the changes continue. The vaginal walls become progressively thinner. Lubrication decreases further. The tissue becomes more fragile, more easily torn, and more vulnerable to infection. For some women, the vaginal canal narrows over time. The 2025 AUA/SUFU/AUGS guideline explicitly identifies GSM as a chronic condition requiring long-term management.
The clinical implication is clear: the earlier you treat vaginal dryness, the easier it is to restore tissue health. Tissue that has thinned over a decade is harder to restore than tissue treated within the first year or two of symptom onset. Waiting is not neutral. It has a cost.
Hot flashes often recalibrate on their own. Vaginal dryness does not. The biology works in one direction without intervention.
What to Try First: Over-the-Counter Options
For mild vaginal dryness, over-the-counter vaginal moisturizers and lubricants are the recommended starting point. These are two different products, and using only one while neglecting the other is a common reason women feel their efforts aren’t working.
Vaginal Moisturizers
Moisturizers are applied regularly — typically two to three times per week — to maintain hydration in the vaginal tissue independent of sexual activity. They work by adhering to the vaginal wall and holding moisture, helping to partially restore the tissue’s comfort baseline. They are not a lubricant for sex. They are an ongoing tissue-health intervention.
The two most commonly recommended options are Revaree (a hyaluronic acid vaginal insert) and Replens (a polycarbophil-based gel). Both are non-hormonal and have clinical support. They have different mechanisms, different formats, and different user experiences — and the choice between them is worth understanding in detail.
Lubricants
Lubricants are used during sexual activity to reduce friction and pain. They do not treat the underlying tissue changes — they manage the symptom during the specific activity where friction is most problematic. Water-based lubricants are generally recommended. Oil-based lubricants can damage condoms and may increase infection risk. Lubricants containing glycerin, warming agents, or fragrances can irritate already-sensitive tissue and should be avoided.
The Mistake Most Women Make
Using only a lubricant during sex without a regular moisturizer between encounters. The lubricant addresses friction. The moisturizer addresses the tissue. You almost certainly need both.
The Gold Standard: Low-Dose Vaginal Estrogen
For moderate to severe vaginal dryness, low-dose vaginal estrogen is the most effective treatment available. The 2025 AUA/SUFU/AUGS guideline issues a strong recommendation that clinicians should offer vaginal estrogen to patients with GSM to improve dryness, discomfort, and painful sex.
Vaginal estrogen works locally. It is applied directly to vaginal tissue — as a cream, tablet, suppository, or ring — and rebuilds the epithelial cell layers, restores elasticity, improves lubrication, normalizes pH, and supports the return of healthy Lactobacillus flora. Improvements typically begin within a few weeks of starting treatment.
This is not the same as systemic hormone therapy. Vaginal estrogen has minimal absorption into the bloodstream. It does not carry the same risk profile as oral or transdermal HRT.
In November 2025, the FDA removed the boxed warning from low-dose vaginal estrogen products. The original warning, applied broadly in 2003 following the Women’s Health Initiative study, was based on oral conjugated estrogens in women with an average age of 63 — a different therapy, a different population, and a different risk profile. The FDA, The Menopause Society, the AUA, ACOG, and international menopause organizations all determined that the warning did not reflect the established safety of local vaginal estrogen.
If your doctor has not offered vaginal estrogen, you are allowed to ask for it. If they are unfamiliar with the updated guidelines, a menopause-certified provider can be found through The Menopause Society’s directory.
Note for breast cancer survivors: The safety of vaginal estrogen in women with estrogen-receptor-positive breast cancer is an evolving area. Recent evidence is increasingly reassuring, but this conversation belongs with your oncology team, not a wellness platform. Non-hormonal options remain fully available and effective regardless of cancer history.
Other Prescription Options
Vaginal DHEA (Prasterone)
An intravaginal insert of dehydroepiandrosterone, which is converted locally into both estrogens and androgens. FDA-approved for moderate to severe GSM-related painful sex. The 2025 AUA guideline gives it a moderate-strength recommendation for improving dryness and dyspareunia. Used nightly.
Ospemifene
An oral selective estrogen receptor modulator (SERM) that acts on vaginal tissue without being estrogen. FDA-approved for moderate to severe vaginal dryness and painful sex due to menopause. Taken as a daily pill. May be appropriate for women who prefer an oral medication over vaginal application.
What Your Doctor Needs to Hear
If vaginal dryness is affecting your comfort, your sex life, or your daily quality of life — name it. The data shows that most clinicians do not proactively ask about vaginal symptoms. This means you will likely need to initiate the conversation.
Here is a sentence you can take to your appointment:
“I am experiencing persistent vaginal dryness that is affecting my quality of life. I understand this may be Genitourinary Syndrome of Menopause. I’d like to discuss vaginal estrogen and other treatment options.”
That framing names the symptom, uses the clinical term, and opens the door to the treatment conversation — rather than waiting for a provider who may never bring it up.
The Bottom Line
Vaginal dryness in menopause is not a cosmetic inconvenience. It is a tissue-level change caused by estrogen decline, part of a recognized medical condition, and it gets progressively worse without treatment. It is also treatable — effectively, safely, and at every level of severity.
You do not have to accept this. You do not have to manage it with silence or avoidance. And you do not have to wait for your doctor to bring it up.
Start with a moisturizer. Talk to your provider about vaginal estrogen. And if no one has told you this before, let me be direct: you deserve comfort in your own body. That is not a luxury. It is a baseline.